Compare Amphastar Pharmaceuticals Inc (AMPH) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Church & Dwight Co., Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Church & Dwight Co., Inc. trades at $97.48 (market cap $22.83B). The key difference: Church & Dwight Co., Inc. is far larger — about 27.6× Amphastar Pharmaceuticals Inc's market cap, and Church & Dwight Co., Inc. pays a 1.28% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CHD | |
|---|---|---|
Market Cap | $826.08M | $22.83B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $105.26 |
52-Week Low | $16.87 | $81.60 |
Enterprise Value | $1.22B | $24.53B |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Church & Dwight (CHD) trades at $96.36, up 0.72% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 adjusted EPS of $0.95, exceeding expectations, driven by 5% organic sales growth. Recent acquisition of Miss Mouth's brand for $325 million aims to strengthen its fabric care portfolio. Cash flow trends show a net outflow in 2025, though operating cash flow remains robust at $1.22 billion.
Outlook remains positive with a consensus price target of $101.33, implying 5% upside, supported by strong analyst sentiment (53% buy ratings). Risks include margin pressure from inflation and competitive threats in consumer staples. The stock's valuation at 31.7x P/E requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
